Etanercept Shortage: What Providers and Prescribers Need to Know in 2026

Etanercept (Enbrel) remains one of the most widely prescribed TNF inhibitors for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. But despite being off patent in most markets, US patients continue to face significant access challenges in 2026. As a prescriber, understanding the systemic barriers — and having strategies to work around them — is essential to maintaining continuity of care for your patients.

Current FDA Shortage Status

Etanercept is not listed in the FDA Drug Shortage Database as of 2026. Amgen and Pfizer continue manufacturing at full capacity, and there are no known supply disruptions at the manufacturing or distribution level. The access problems your patients report are not driven by a shortage in the traditional sense, but by structural and financial barriers in the US specialty drug distribution system.

The Biosimilar Landscape: Why US Patients Are Still Locked Out

Two etanercept biosimilars have FDA approval — Erelzi (etanercept-szzs, Sandoz) approved in 2016 and Eticovo (etanercept-ykro, Samsung Bioepis) approved in 2019. However, neither is commercially available in the United States due to a manufacturing process patent held by Amgen that extends through 2029.

Both Sandoz and Samsung Bioepis pursued patent challenges, and both were denied by US courts. This is a stark contrast to the European market, where multiple etanercept biosimilars have been available since 2016 and have significantly reduced treatment costs. US clinicians and patients will not benefit from biosimilar price competition until at least 2029.

Clinical note for switching: If a patient currently on etanercept needs to switch due to access or cost issues, TNF inhibitor switching to adalimumab (Humira) or its biosimilars is a clinically reasonable option for most indications. Evidence supports that switching between TNF inhibitors for non-medical reasons does not significantly compromise efficacy for most patients.

Prior Authorization Challenges: What Your Patients Are Experiencing

For patients, the biggest access barrier is prior authorization. Key issues providers should anticipate:

Step therapy requirements. Most commercial plans and many Medicare Part D formularies require documented inadequate response to methotrexate (and sometimes a second conventional DMARD) before approving etanercept. Ensure your notes document treatment history and clinical rationale for biologics clearly.

PA expiration timing. Most plans grant 12-month PA approvals. Remind your practice staff to initiate renewal 3-4 weeks before expiration. A lapse causes a supply disruption even when no clinical change has occurred.

Insurance changes (especially January 1) frequently trigger new PA requirements. Proactively submit PAs for patients whose insurance changes at year-end open enrollment.

Appeal support: Letters of medical necessity should cite specific clinical criteria — ACR score, functional status, prior DMARD failure with dates, and clinical evidence supporting biologic use.

Financial Barriers and Patient Assistance Programs

At a list price of approximately $8,000-$11,000 per month, etanercept is unaffordable for most patients without coverage. Key programs to know:

Enbrel SupportPlus Copay Card: For commercially insured patients, may reduce costs to as little as $0 per month (up to $12,000 per year). Not valid for Medicare, Medicaid, or federal program enrollees.

Amgen Safety Net Foundation: Provides free Enbrel to qualifying uninsured and underinsured patients. Income limits apply.

Medicare IRA Cap: Part D out-of-pocket spending is capped at $2,000/year starting 2025. CMS selected etanercept for drug price negotiation with a targeted price of approximately $2,355/month for Medicare.

Clinical Alternatives to Consider When Etanercept Is Inaccessible

When etanercept access fails and time is critical:

Adalimumab biosimilars (Hadlima, Hyrimoz, Cyltezo, etc.): Same drug class; full US market competition driving lower prices; approved for all overlapping etanercept indications.

Certolizumab pegol (Cimzia): Preferred in pregnancy-relevant cases; less placental transfer.

Abatacept (Orencia): Reasonable alternative for RA; remember it is contraindicated in combination with etanercept.

Secukinumab (Cosentyx): Preferred in AS and PsA per ACR/EULAR guidance for patients with inflammatory bowel disease or frequent infections.

How medfinder Supports Your Patients

When a patient reports they cannot find etanercept at their pharmacy, medfinder for providers gives your care team a resource to direct them to immediately. medfinder calls pharmacies on the patient's behalf, checks which ones can fill the prescription, and texts the patient results — cutting out hours of frustrating phone calls during an already stressful situation.

For a more detailed workflow for your practice, see our companion guide: How to help your patients find etanercept in stock.